MedTrace Logo

Sub-Clinical Atrial Fibrillation Biomarker Study

NCT02840201 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 321

Last updated 2026-05-06

No results posted yet for this study

Summary

This is a sub-study of the ARTESiA study registered as NCT01938248. This study is designed to validate biomarkers in subclinical atrial fibrillation and to determine if the prospective biomarker will be informative of the potential efficacy of treatment.

Conditions

  • Subclinical Atrial Fibrillation

Sponsors & Collaborators

  • Population Health Research Institute

    collaborator OTHER

  • Genome Canada

    collaborator OTHER

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Pfizer

    collaborator INDUSTRY

  • Medtronic

    collaborator INDUSTRY

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Ottawa Heart Institute Research Corporation

    lead OTHER

Principal Investigators

  • Peter Liu, MD · Ottawa Heart Institute Research Corporation

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-26
Primary Completion
2025-09-30
Completion
2025-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02840201 on ClinicalTrials.gov